Rocket Lab's Bullish Narrative Faces Filing Reality

What happened

A Zacks article touts Rocket Lab's $2 billion backlog and Neutron rocket as positioning it as the premier public SpaceX alternative, fueling bullish sentiment. However, the DeepValue report reveals significant schedule risks after a January 2026 first-stage tank failure pushed Neutron's first launch to Q4 2026, with explicit timeline uncertainty. The report also highlights material dilution risk: Rocket Lab raised $450.3 million via ATM in Q1 2026 and authorized up to $1.0 billion in additional equity sales, while insider selling clustered in early March 2026. Despite strong Q1 results ($200.3M revenue, 38.2% gross margin), the company still burned $50.3M in operating cash and only 36% of backlog is expected within 12 months. The market narrative is pricing in a high-confidence Neutron schedule and sustained backlog conversion, but filings show fragility that could lead to per-share value impairment.

Implication

The stock lacks a margin of safety at $78.6. Investors should hold off until two quarters confirm sustained revenue and margin conversion without repeat Q1-scale dilution. If Neutron timeline slips beyond Q4 2026 or dilution accelerates, the thesis breaks. The attractive entry is below $65, with trim above $95.

Thesis delta

The thesis shifts from 'wait for proof' to 'pricing already discounts high-confidence execution, but filings show the opposite.' The bullish narrative driven by Zacks ignores the explicit schedule risk from the tank failure and the aggressive dilution that could erode per-share value. Investors should demand operational proof—not just backlog size—before committing capital.